C83.18 Mantle cell lymphoma, lymph nodes of multiple sites

Name of the Condition

• Mantle cell lymphoma, lymph nodes of multiple sites
• Also known as ICD-10 code C83.18

Summary

Mantle cell lymphoma, lymph nodes of multiple sites, is a type of non-Hodgkin lymphoma characterized by the malignant proliferation of B-cells originating from the mantle zone of lymphoid follicles. It specifically involves abnormal growth of these cells in lymph nodes across multiple anatomical sites. This condition is part of the broader category of non-follicular lymphomas and may present with variable clinical behavior.

Causes

The exact cause of mantle cell lymphoma, lymph nodes of multiple sites, remains unknown. It is thought to involve genetic mutations, such as the t(11;14)(q13;q32) translocation, which leads to overexpression of cyclin D1. Specific triggers or environmental factors are not well-defined, though research suggests potential links to immune system dysregulation.

Risk Factors

• Age: More common in older adults, typically over 60 years.
• Male gender: Slightly higher incidence in males.
• Family history of lymphoma.
• Prior exposure to radiation or certain chemicals.
• Chronic infections, such as hepatitis C or HIV.
• Immunosuppressive conditions or treatments.

Symptoms

• Swollen, painless lymph nodes in multiple regions.
• Unexplained weight loss.
• Fever.
• Night sweats.
• Fatigue.
• Loss of appetite.
• Abdominal pain or fullness (if spleen or gastrointestinal tract is involved).

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT or PET scans), and laboratory tests. A definitive diagnosis typically requires a biopsy of affected lymph nodes, followed by histopathological examination and immunophenotyping to confirm the presence of mantle cell lymphoma. Additional tests, such as flow cytometry or molecular studies, may be used to identify characteristic genetic abnormalities.

Treatment Options

Treatment depends on the stage of the disease, patient age, and overall health. Options may include chemotherapy, targeted therapy (e.g., BTK inhibitors), immunotherapy, or stem cell transplantation. Radiation therapy may be used for localized disease or symptom control. Treatment plans are often individualized and may involve a multidisciplinary approach.

Prognosis and Follow-Up

Prognosis varies based on factors such as disease stage, response to treatment, and patient age. Regular follow-up is essential to monitor for recurrence or progression. Follow-up care may include periodic imaging, blood tests, and clinical assessments to detect any changes in the condition.

Complications

Potential complications include disease progression, treatment-related side effects (e.g., infection, organ toxicity), and transformation to a more aggressive lymphoma subtype. Other risks may include bone marrow involvement leading to cytopenias or organ dysfunction due to lymph node enlargement.

Lifestyle & Prevention

No specific lifestyle changes can prevent mantle cell lymphoma. Maintaining overall health, avoiding known carcinogens, and managing chronic infections may support general well-being. Patients should follow recommended screening and vaccination guidelines, especially if immunosuppressed.

When to Seek Professional Help

Seek medical attention if you experience persistent swollen lymph nodes, unexplained weight loss, fever, night sweats, or fatigue. Early evaluation is important for timely diagnosis and treatment planning.

Tips for Medical Coders

When coding for mantle cell lymphoma, lymph nodes of multiple sites (C83.18), ensure documentation specifies involvement of multiple lymph node regions. Verify that the diagnosis aligns with histopathological and clinical findings. Accurate coding requires clear documentation of the affected sites to support the specificity of this code.